Skip to main content
Mersana Therapeutics, Inc. logo

Mersana Therapeutics, Inc. — Investor Relations & Filings

Ticker · MRSN ISIN · US59045L1061 LEI · 529900VWD5VDZ7PVOS22 US Manufacturing
Open in API
Filings indexed 700 across all filing types
Latest filing 2022-02-11 Major Shareholding Noti…
Country US United States of America
Listing US MRSN

About Mersana Therapeutics, Inc.

https://www.mersana.com/

Mersana Therapeutics, Inc. is a clinical-stage company focused on discovering and developing life-changing antibody-drug conjugates (ADCs) for patients fighting cancer. The company utilizes its proprietary and differentiated ADC platforms, which incorporate both cytotoxic and immunostimulatory payloads, to develop its pipeline. These platforms are designed to customize and optimize ADCs, aiming to overcome the limitations of first-generation technologies by improving efficacy and tolerability. Mersana is advancing a portfolio of ADC candidates to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2022
Major Shareholding Notification
2022-02-11 English
SCHEDULE 13G
Major Shareholding Notification
2022-02-10 English
FORM 4 SUBMISSION
Director's Dealing
2022-02-08 English
SC 13D/A
Major Shareholding Notification
2022-02-08 English
SEC SCHEDULE 13G
Major Shareholding Notification
2022-02-04 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes a material definitive agreement (a research collaboration and license agreement) and an amendment related to a loan agreement. There are no financial statements or detailed financial performance data, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a call transcript, earnings release, or governance information. The document is an announcement of a significant contract and financing update. Given the nature of the content—announcement of a material agreement and loan amendment—the best fitting category is Capital/Financing Update (CAP). The document length is sufficient and contains substantive details about the agreement and financing terms, supporting this classification with high confidence.
2022-02-03 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.